Scopus BioPharma Inc.: Nasdaq/NYSE listing notice — Scopus BioPharma receives Nasdaq delisting notice; trading suspended Dec 19

Scopus BioPharma Inc.

Nasdaq Panel determined to delist SCPS after company failed to meet compliance milestones, including a specified financing transaction.
Nasdaq trading will be suspended effective at the open on December 19, 2022.
Company expects to trade on OTC Markets under same ticker SCPS; has applied for the OTCQB Venture Market.
No assurance OTCQB application will be approved or that company can satisfy ongoing reporting requirements.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Scopus BioPharma Inc. received a nasdaq delisting notice notice.

Exchange: nasdaq
Notice: delisting notice

Exact text from the filing

December 15, 2022, of its determination to delist the Company’s common stock from Nasdaq. Such letter further informed the Company that Nasdaq will complete the delisting after, among other things, the lapsing of applicable appeal periods and that trading of the Company’s common stock on Nasdaq will be suspended effective at the open of trading on December 19, 2022. The Company anticipates that, upon suspension of trading on Nasdaq, its common stock will commence trading on one of the markets operated by the OTC Markets Group under its existing ticker symbol “SCPS”. The Company has submitted a

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001104659-22-127517

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.